Prevalence of zidovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment

N. Principi

Research output: Contribution to journalArticle

Abstract

Objective: To determine type and prevalence of ndovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment Methods: HIV+ children with symptomatic infection who had received at least 16 weeks of zidovudine were enrolled. Children were classified according to CDC criteria. 1994. Proviral DNA was obtained from PBMC and POL gene analyzed by nested PCR using a sequence analyzer for mutations at codon 41,67.69,70,215,219. Results: One hundred and ten children were enrolled The median age was 63 months (range 9-141 months); the median duration of zidovudine therapy was 21 months (range 471 ). Mutations were present in 93 (84.5%) children: 29 had one mutation ( 13 at codon 70. 15 at codon 215), 35 had two mutations (19 at codons 41 and 215), 18 had 3 mutations. 10 had 4 mutations and one child had 6 mutations. The number of mutations was significantly correlated with the age of the child and the duration of zidovudine treatment before study entryThe presence of mutations did not correlate with the severity of immunodeficiency. Conclusions: Zidovudine resistance mutations are highly prevalent in children who had received long-term zidovudine.The type and the prevalence of mutations are similar to those found in adult studies. Further studies are needed to clarify the clinical significance of multiple resistance mutations.

Original languageEnglish
Pages (from-to)464
Number of pages1
JournalPediatric AIDS and HIV Infection
Volume7
Issue number6
Publication statusPublished - 1996

Fingerprint

Zidovudine
HIV
Mutation
Codon
Therapeutics
Centers for Disease Control and Prevention (U.S.)

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Prevalence of zidovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment. / Principi, N.

In: Pediatric AIDS and HIV Infection, Vol. 7, No. 6, 1996, p. 464.

Research output: Contribution to journalArticle

@article{d67373e647d14a079c749f7447891e56,
title = "Prevalence of zidovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment",
abstract = "Objective: To determine type and prevalence of ndovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment Methods: HIV+ children with symptomatic infection who had received at least 16 weeks of zidovudine were enrolled. Children were classified according to CDC criteria. 1994. Proviral DNA was obtained from PBMC and POL gene analyzed by nested PCR using a sequence analyzer for mutations at codon 41,67.69,70,215,219. Results: One hundred and ten children were enrolled The median age was 63 months (range 9-141 months); the median duration of zidovudine therapy was 21 months (range 471 ). Mutations were present in 93 (84.5{\%}) children: 29 had one mutation ( 13 at codon 70. 15 at codon 215), 35 had two mutations (19 at codons 41 and 215), 18 had 3 mutations. 10 had 4 mutations and one child had 6 mutations. The number of mutations was significantly correlated with the age of the child and the duration of zidovudine treatment before study entryThe presence of mutations did not correlate with the severity of immunodeficiency. Conclusions: Zidovudine resistance mutations are highly prevalent in children who had received long-term zidovudine.The type and the prevalence of mutations are similar to those found in adult studies. Further studies are needed to clarify the clinical significance of multiple resistance mutations.",
author = "N. Principi",
year = "1996",
language = "English",
volume = "7",
pages = "464",
journal = "Pediatric AIDS and HIV Infection",
issn = "1045-5418",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Prevalence of zidovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment

AU - Principi, N.

PY - 1996

Y1 - 1996

N2 - Objective: To determine type and prevalence of ndovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment Methods: HIV+ children with symptomatic infection who had received at least 16 weeks of zidovudine were enrolled. Children were classified according to CDC criteria. 1994. Proviral DNA was obtained from PBMC and POL gene analyzed by nested PCR using a sequence analyzer for mutations at codon 41,67.69,70,215,219. Results: One hundred and ten children were enrolled The median age was 63 months (range 9-141 months); the median duration of zidovudine therapy was 21 months (range 471 ). Mutations were present in 93 (84.5%) children: 29 had one mutation ( 13 at codon 70. 15 at codon 215), 35 had two mutations (19 at codons 41 and 215), 18 had 3 mutations. 10 had 4 mutations and one child had 6 mutations. The number of mutations was significantly correlated with the age of the child and the duration of zidovudine treatment before study entryThe presence of mutations did not correlate with the severity of immunodeficiency. Conclusions: Zidovudine resistance mutations are highly prevalent in children who had received long-term zidovudine.The type and the prevalence of mutations are similar to those found in adult studies. Further studies are needed to clarify the clinical significance of multiple resistance mutations.

AB - Objective: To determine type and prevalence of ndovudine resistance mutations in HIV isolated from children after long-term zidovudine treatment Methods: HIV+ children with symptomatic infection who had received at least 16 weeks of zidovudine were enrolled. Children were classified according to CDC criteria. 1994. Proviral DNA was obtained from PBMC and POL gene analyzed by nested PCR using a sequence analyzer for mutations at codon 41,67.69,70,215,219. Results: One hundred and ten children were enrolled The median age was 63 months (range 9-141 months); the median duration of zidovudine therapy was 21 months (range 471 ). Mutations were present in 93 (84.5%) children: 29 had one mutation ( 13 at codon 70. 15 at codon 215), 35 had two mutations (19 at codons 41 and 215), 18 had 3 mutations. 10 had 4 mutations and one child had 6 mutations. The number of mutations was significantly correlated with the age of the child and the duration of zidovudine treatment before study entryThe presence of mutations did not correlate with the severity of immunodeficiency. Conclusions: Zidovudine resistance mutations are highly prevalent in children who had received long-term zidovudine.The type and the prevalence of mutations are similar to those found in adult studies. Further studies are needed to clarify the clinical significance of multiple resistance mutations.

UR - http://www.scopus.com/inward/record.url?scp=33747465846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747465846&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 464

JO - Pediatric AIDS and HIV Infection

JF - Pediatric AIDS and HIV Infection

SN - 1045-5418

IS - 6

ER -